<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table5" position="float"><object-id pub-id-type="doi">10.7554/eLife.33478.011</object-id><label>Table 5.</label><caption><title>Summary of disability and death by day 60 and by 8 months in the ITT and per-protocol populations</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">Placebo (N&#160;=&#160;41)</th><th valign="top">Aspirin 81 mg (N&#160;=&#160;39)</th><th valign="top">Aspirin 1000 mg (N&#160;=&#160;40)</th><th valign="top">P-value</th></tr></thead><tbody><tr><td colspan="5" valign="top">ITT population</td></tr><tr><td valign="top">Rankin score categories by 60 days*</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;- Complete recovery</td><td valign="top">6/37 (16.2%)</td><td valign="top">11/39 (28.2%)</td><td valign="top">9/40 (22.5%)</td><td valign="top"/></tr><tr><td valign="top">&#8195;- Intermediate</td><td valign="top">22/37 (59.5%)</td><td valign="top">16/39 (41.0%)</td><td valign="top">22/40 (55.0%)</td><td valign="top">0.61</td></tr><tr><td valign="top">&#8195;- Death or severely disabled</td><td valign="top">9/37 (24.3%)</td><td valign="top">12/39 (30.8%)</td><td valign="top">9/40 (22.5%)</td><td valign="top"/></tr><tr><td valign="top">Rankin score categories by 8 months</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;- Complete recovery</td><td valign="top">18/39 (46.1%)</td><td valign="top">23/39 (59.0%)</td><td valign="top">22/40 (55.0%)</td><td valign="top"/></tr><tr><td valign="top">&#8195;- Intermediate</td><td valign="top">10/39 (24.6%)</td><td valign="top">7/39 (17.95%)</td><td valign="top">11/40 (27.5%)</td><td valign="top">0.29</td></tr><tr><td valign="top">&#8195;- Death or severely disabled</td><td valign="top">11/39 (28.2%)</td><td valign="top">9/39 (23.1%)</td><td valign="top">7/40 (17.5%)</td><td valign="top"/></tr><tr><td colspan="5" valign="top"><bold>Per-protocol population</bold></td></tr><tr><td valign="top">Rankin score categories at 60 days</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;- Complete recovery</td><td valign="top">6/33 (18.2%)</td><td valign="top">9/31 (29.0%)</td><td valign="top">7/31 (22.6%)</td><td valign="top"/></tr><tr><td valign="top">&#8195;- Intermediate</td><td valign="top">21/33 (63.6%)</td><td valign="top">15/31 (48.4%)</td><td valign="top">19/31 (61.3%)</td><td valign="top">0.69</td></tr><tr><td valign="top">&#8195;- Death or severely disabled</td><td valign="top">6/33 (18.2%)</td><td valign="top">7/31 (22.6%)</td><td valign="top">5/31 (16.1%)</td><td valign="top"/></tr><tr><td valign="top"><bold>Rankin score categories by 8 months</bold></td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;- Complete recovery</td><td valign="top">17/35 (48.6%)</td><td valign="top">20/31 (64.5%)</td><td valign="top">19/31 (61.3%)</td><td valign="top"/></tr><tr><td valign="top">&#8195;- Intermediate</td><td valign="top">9/35 (25.7%)</td><td valign="top">5/31 (16.1%)</td><td valign="top">9/31 (29.0%)</td><td valign="top">0.13</td></tr><tr><td valign="top">&#8195;- Death or severely disabled</td><td valign="top">9/35 (25.7%)</td><td valign="top">6/31 (19.4%)</td><td valign="top">3/31 (9.7%)</td><td valign="top"/></tr></tbody></table><table-wrap-foot><fn><p>*Complete recovery&#160;=&#160;Rankin score 0; Intermediate&#160;=&#160;Rankin score 1 or 2; Death or severely disabled&#160;=&#160;Rankin score 3&#8211;6. Three participants in the placebo group missed their day 60 assessment and two were lost to follow-up at day 57 and 217. P-values refer to a linear-by-linear trend test for disability scores</p></fn></table-wrap-foot></table-wrap>